Navigation Links
Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007

mean change in serum creatinine in patients treated with the highest dose of KW-3902 compared to a 0.2 milligram per deciliter mean increase, or worsening, in participants receiving placebo. These data are consistent with prior findings and indicate that KW-3902 appears to have a persistent effect on renal function. To date, no other vasodilator has demonstrated the selective renal vasodilation attribute of KW-3902 that is critical for preserving renal function.

About Congestive Heart Failure

Congestive heart failure (CHF) is a widespread and debilitating disease most often caused by a weakening or stiffening of the heart muscle, which leads to a progressive loss in the heart's ability to pump blood effectively throughout the body. There are nearly five million people in the United States with CHF, according to the American Heart Association (AHA). With the aging population and more patients surviving the early stages of cardiovascular diseases, the prevalence of CHF is increasing. Approximately 550,000 new cases of CHF are reported in the United States each year, according to the AHA.

About NovaCardia

NovaCardia is a clinical-stage pharmaceutical company focused on developing drugs to treat major cardiovascular diseases that are underserved by existing therapies. The company has two compounds in clinical development, KW-3902 for congestive heart failure and K-201 (JTV-519) for atrial fibrillation.

NovaCardia cautions you that statements included in this press release that are not a description of historical facts, including implied statements relating to future outcomes of clinical trials, may be forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in NovaCardia's business including, without limitation, risks related to difficulties or delays in, testing, obtaining regulatory approval, producing
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:12/24/2014)... PRINCETON, N.J. , Dec. 24, 2014 /PRNewswire/ ... Company), a late-stage biopharmaceutical company developing products that ... inflammation, oncology and biodefense, announced today that on ... registered public offering. The Company raised ... offering and intends to use the net proceeds ...
(Date:12/24/2014)... and LONDON , December 24, 2014 ... are expected to grow at an average rate of ... value and volume. Hip, knee and spine surgeries are ... in emerging economies they have a lower penetration. Increased ... the use of composites. Non-metallic orthopedic devices have gained ...
(Date:12/24/2014)... 2014 LifeScienceIndustryResearch.com adds ... Syringe Industry of 178 pages providing 10 ... library. The 2014 Market Research ... a professional and deep research report on ... the report introduces Disposable Syringe basic information ...
Breaking Medicine Technology:Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5
... , May 8 Inverness Medical Innovations, Inc. (NYSE: ... take charge of their health at home through the merger of ... the Bank of America Merrill Lynch Health Care Conference being held ... in New York, New York .  Jon Russell, Vice President, ...
... SWANTON, Vt ., May 7 This May, ... in their effort to spread Multiple Chemical Sensitivity Syndrome awareness.   , ... AllerAir will make chemical awareness ... at www.allerair.com .  Additionally, their blogs and articles ...
Cached Medicine Technology:Multiple Chemical Sensitivities Are Real 2Multiple Chemical Sensitivities Are Real 3
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... on a "fountain of youth" drug that can delay the ... a new study suggests. Seniors received a significant boost ... a genetic signaling pathway linked to aging and immune function, ... The experimental medication, a version of the drug rapamycin, improved ...
(Date:12/25/2014)... December 25, 2014 Thousands of transvaginal ... forward in a number of multidistrict litigations currently underway ... Bernstein Liebhard LLP reports. According to an Order issued ... convene a Joint Status Conference in all of the ... have been directed to submit a proposed agenda to ...
(Date:12/25/2014)... 25, 2014 Plugin creators from Pixel ... A fully customizable business presentation tool made specifically for ... ProFire 5k business tool, users can now display their ... of Pixel Film Studios. “ProFire 5k gives users a ... add professionalism to a presentation” , Pixel Film Studios ...
(Date:12/25/2014)... CA (PRWEB) December 25, 2014 Each ... visits and 2 million hospital admissions across the nation ... Prevention ). The CDC’s National Hospital Ambulatory Medical ... through a survey conducted in 2010. They estimated that ... visits that resulted in a primary diagnosis of broken ...
(Date:12/24/2014)... Wi (PRWEB) December 25, 2014 AlignLife ... are unable to afford certain items. During the holiday season, ... "We collected over 70 toys," says Dr. Sara Mahalko-Leonhardt, owner ... and staff such joy, knowing that we are able to ... present had it not been for the generosity of our ...
Breaking Medicine News(10 mins):Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2
... prescription drugs , THURSDAY, April 8 (HealthDay News) -- Medical ... included -- are poorly informed about herbal medicines and that ... misplaced, according to a new survey. , The survey was ... and Therapeutics Bulletin , which published the results online April ...
... ... Research Behind Their Products , ... Provo, UT (Vocus) April 8, 2010 -- Tahitian Noni International (TNI) now has ... are on the way. TNI has more human clinical studies than any network marketing superfruit ...
... Thomas Mower Sr., Chairman of ... in the growth and success of Sportsmen for Fish and Wildlife (SFW), according to Founder Don ... Salt Lake City (PRWEB) April ... of the Utah Jazz, have been key players in the growth and success of Sportsmen for ...
... ... Medical Design Excellence Awards competition, one of the most prestigious awards in the medical ... ... recognized in the 2010 Medical Design Excellence Awards competition, one of the most prestigious ...
... ... week to discuss how to start your own porn site. , ... (PRWEB) April 8, 2010 -- The Phoenix Forum is Thursday, April 8th ... of Teleteria would love to go over ways to improve your traffic and revenue stream in ...
... ... and positioning of healthcare technology solutions. , ... (PRWEB) April 8, 2010 -- CapSite™ Consulting, ... comparisons of contracts and proposals for Healthcare IT, Imaging Equipment and Medical Device ...
Cached Medicine News:Health News:Insight on Herbals Eludes Doctors, Patients Alike 2Health News:14 Human Clinical Studies Prove the Efficacy of Tahitian Noni Bioactive Beverages 2Health News:Thomas E. Mower And Karl Malone Instrumental To Success Of Sportsmen For Fish And Wildlife Organization 2Health News:Thomas E. Mower And Karl Malone Instrumental To Success Of Sportsmen For Fish And Wildlife Organization 3Health News:Thomas E. Mower And Karl Malone Instrumental To Success Of Sportsmen For Fish And Wildlife Organization 4Health News:ROBRADY Design's Work with Xhale Innovations Inc. Wins 2010 Medical Design Excellence Awards 2Health News:ROBRADY Design's Work with Xhale Innovations Inc. Wins 2010 Medical Design Excellence Awards 3Health News:Jay Servidio President Teleteria Appearances To Discuss The Porn Business This Week 2Health News:CapSite™ Provides Detailed Transparency on Healthcare Technology Purchases 2
... agitators offer a wide range of storage ... drawer storage platform to agitate smoothly, eliminating ... down and squeak. Sturdy, one-piece perforated drawers ... circulation for your platelets., ,i.Series platelet agitators ...
Platelet agitator....
Reciprocating shaker specifically for platelet bags....
I-125 competitive RIA kit for the detection of Progesterone....
Medicine Products: